Article
Author(s):
Vedolizumab (Entyvio) is indicated for adult patients with moderately to severely active ulcerative colitis and adult patients with moderately to severely active Crohn disease.
Medication Pearl of the Day: Vedolizumab (Entyvio)
Indication: Vedolizumab (Entyvio) is an integrin receptor antagonist indicated for adult patients with moderately to severely active ulcerative colitis (UC) and adult patients with moderately to severely active Crohn disease (CD).
Insight:
Source:
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children At Increased Risk